Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib for Acute Myeloid Leukemia
NCT01174043Phase 2Completed
- Sponsor
- Indiana University
- Start
- Jul 2010
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of erlotinib in acute myeloid leukemia (AML), sponsored by Indiana University. Primary endpoint: Overall Response Rate at 3 months. Started Jul 2010; status: completed.
02
Drugs
erlotinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01174043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01174043.